AG
SUPN icon

Aperio Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Aperio Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$697K Sell
27,707
-8,257
-23% -$178K ﹤0.01% 1796
2020
Q3 		$750K Buy
35,964
+6,578
+22% +$149K ﹤0.01% 1590
2020
Q2 		$698K Buy
29,386
+2,710
+10% +$59.9K ﹤0.01% 1594
2020
Q1 		$480K Buy
26,676
+8,869
+50% +$186K ﹤0.01% 1670
2019
Q4 		$422K Buy
17,807
+1,906
+12% +$46.3K ﹤0.01% 1895
2019
Q3 		$437K Buy
15,901
+2,344
+17% +$69.5K ﹤0.01% 1833
2019
Q2 		$449K Sell
13,557
-4,874
-26% -$167K ﹤0.01% 1845
2019
Q1 		$646K Buy
18,431
+1,392
+8% +$51.8K ﹤0.01% 1597
2018
Q4 		$566K Sell
17,039
-120
-0.7% -$5.16K ﹤0.01% 1606
2018
Q3 		$864K Sell
17,159
-572
-3% -$28.2K ﹤0.01% 1486
2018
Q2 		$1.06M Buy
17,731
+2,948
+20% +$153K 0.01% 1348
2018
Q1 		$677K Buy
14,783
+2,104
+17% +$87.8K ﹤0.01% 1545
2017
Q4 		$505K Buy
12,679
+108
+0.9% +$4.27K ﹤0.01% 1700
2017
Q3 		$503K Buy
12,571
+244
+2% +$10.6K ﹤0.01% 1656
2017
Q2 		$531K Buy
12,327
+4,441
+56% +$158K ﹤0.01% 1618
2017
Q1 		$247K Buy
+7,886
New +$211K ﹤0.01% 1923

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Aperio Group's SUPN Position: Q4 2020 in Review

Aperio Group reduced its Supernus Pharmaceuticals (SUPN) stake by 23% in Q4 2020, selling an estimated $178K and leaving 27,707 shares worth $697K. The position accounts for ﹤0.01% of the portfolio, ranked #1796.

Aperio Group first reported a position in SUPN in Q1 2017 and has held it in 16 quarters since. The position peaked at $1.06M in Q2 2018. 225 funds tracked by Wall St. Rank hold SUPN as of Q4 2020.

  • Aperio Group held 27,707 shares of Supernus Pharmaceuticals worth $697K as of Q4 2020.
  • Aperio Group sold 8,257 Supernus Pharmaceuticals shares in Q4 2020, an estimated $178K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1796 holding.
  • Aperio Group first reported a position in Supernus Pharmaceuticals in Q1 2017 and has held it in 16 quarters since.
  • Aperio Group's Supernus Pharmaceuticals position peaked at $1.06M in Q2 2018.
  • 225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.